175 related articles for article (PubMed ID: 35143036)
21. Aggressive giant prolactinoma: a case report.
Borhan MK; Tan FHS
J Med Case Rep; 2022 Apr; 16(1):170. PubMed ID: 35488355
[TBL] [Abstract][Full Text] [Related]
22. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
Cackett P; Eunson G; Bath L; Mulvihill A
Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
[TBL] [Abstract][Full Text] [Related]
23. Giant prolactinoma and effectiveness of medical management.
Acharya SV; Gopal RA; Menon PS; Bandgar TR; Shah NS
Endocr Pract; 2010; 16(1):42-6. PubMed ID: 19703803
[TBL] [Abstract][Full Text] [Related]
24. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
Sehemby M; Lila AR; Sarathi V; Shah R; Sankhe S; Jaiswal SK; Ramteke-Jadhav S; Patil V; Shah N; Bandgar T
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942295
[TBL] [Abstract][Full Text] [Related]
25. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy.
Vilar L; Czepielewsk MA; Naves LA; Rollin GA; Casulari LA; Coelho CE
Endocr Pract; 2007; 13(4):396-402. PubMed ID: 17669717
[TBL] [Abstract][Full Text] [Related]
26. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
[TBL] [Abstract][Full Text] [Related]
27. Pituitary apoplexy of a giant prolactinoma during pregnancy.
Khaldi S; Saad G; Elfekih H; Ben Abdelkrim A; Ach T; Kacem M; Chaieb M; Maaroufi A; Hasni Y; Ach K
Gynecol Endocrinol; 2021 Sep; 37(9):863-866. PubMed ID: 34124989
[TBL] [Abstract][Full Text] [Related]
28. Gangliocytoma masquerading as a prolactinoma. Case report.
McCowen KC; Glickman JN; Black PM; Zervas NT; Lidov HG; Garber JR
J Neurosurg; 1999 Sep; 91(3):490-5. PubMed ID: 10470826
[TBL] [Abstract][Full Text] [Related]
29. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.
Cho EH; Lee SA; Chung JY; Koh EH; Cho YH; Kim JH; Kim CJ; Kim MS
J Korean Med Sci; 2009 Oct; 24(5):874-8. PubMed ID: 19794986
[TBL] [Abstract][Full Text] [Related]
31. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
32. Pseudotumor cerebri and prolactin secreting pituitary adenoma. Association or coincidence?
Jamjoom BA; Sharab MA; Nasser TA; Jamjoom AB
Neurosciences (Riyadh); 2010 Jul; 15(3):200-3. PubMed ID: 20831031
[TBL] [Abstract][Full Text] [Related]
33. Combined cabergoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency.
Cesario F; Borretta G; Meineri I; Muratori M; Pizzocaro A; Beck-Peccoz P
J Pediatr Endocrinol Metab; 1997; 10(2):231-6. PubMed ID: 9364359
[TBL] [Abstract][Full Text] [Related]
34. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
35. Prolactinomas in males: any differences?
Duskin-Bitan H; Shimon I
Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
[TBL] [Abstract][Full Text] [Related]
36. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
[TBL] [Abstract][Full Text] [Related]
37. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'.
Fleseriu M; Lee M; Pineyro MM; Skugor M; Reddy SK; Siraj ES; Hamrahian AH
J Neurooncol; 2006 Aug; 79(1):41-3. PubMed ID: 16598425
[TBL] [Abstract][Full Text] [Related]
38. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
39. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
40. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
